Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 25 |
| Active Pipeline (Recruiting Now) | 6 (3) |
| Completed vs Stopped Early | 18 / 1 (4.0%) |
| Median Closed Actual Enrollment | 113 participants |
| Physical Hospital Site Disclosure | 99.2% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Okayama University Hospital | Okayama | 4 |
| Hokkaido University Hospital | Sapporo, Hokkaido | 4 |
| Osaka Metropolitan University Hospital | Osaka | 3 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT04533581 | Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL) | Phase II | ACTIVE NOT RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Kyowa Kirin Co Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.